S. Emri Et Al. , "Diagnostic Utility of Mesothetin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma," JOURNAL OF THORACIC ONCOLOGY , vol.12, no.1, 2017
Emri, S. Et Al. 2017. Diagnostic Utility of Mesothetin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma. JOURNAL OF THORACIC ONCOLOGY , vol.12, no.1 .
Emri, S., Dikmen, G., SARINÇ ULAŞLI, S., Esendagli, D., Yilmaz, U., ŞİMŞEK ÖZEK, N., ... Severcan, F.(2017). Diagnostic Utility of Mesothetin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma. JOURNAL OF THORACIC ONCOLOGY , vol.12, no.1.
Emri, KAHRAMAN Et Al. "Diagnostic Utility of Mesothetin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma," JOURNAL OF THORACIC ONCOLOGY , vol.12, no.1, 2017
Emri, KAHRAMAN A. Et Al. "Diagnostic Utility of Mesothetin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma." JOURNAL OF THORACIC ONCOLOGY , vol.12, no.1, 2017
Emri, S. Et Al. (2017) . "Diagnostic Utility of Mesothetin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma." JOURNAL OF THORACIC ONCOLOGY , vol.12, no.1.
@article{article, author={KAHRAMAN AHMET SALİH EMRİ Et Al. }, title={Diagnostic Utility of Mesothetin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2017}